Literature DB >> 35169367

Population-genetic Aspects of Breast Cancers and Association with Rh Factor in Selected Sample.

Azra Metovic1, Jasmin Musanovic1, Nerman Ramic2, Orhan Lepara3, Damir Secic4, Esad Pepic4, Svjetlana Loga Zec5, Senad Sljuka6.   

Abstract

BACKGROUND: Breast cancer in women is the second most common and accounts for approximately 18% of all malignant tumors in women worldwide. The etiology of breast cancer is not clear enough. Starting from the assumption that the manifestation of breast cancer may have a multifactorial model, this article compares the population-genetic structure of patients (experimental group) with the population-genetic structure of healthy population (control group).
OBJECTIVE: The aim of the study was to examine the possible genetic basis of the Rh factor relationship with selected homozygous-recessive traits of females with breast cancer, and to diagnose the probability (assess the risk) of developing the disease in healthy women by analyzing homozygous-recessive traits (HRT).
METHODS: This are an anthroposcopic-qualitative study that included two groups of subjects, experimental and control (a total of 80 subjects). An analysis of the percentages within each group was performed using the Chi-square test. The results are presented in tables, and the accepted level of significance is at the level of p <0.05.
RESULTS: In the group of Rh+ subjects, the correlation of this type of Rh factor with the breast cancer was proven, given the frequency of the phenotype of homozygous-recessive traits in them. A statistically significant difference was found for 4 traits, and three are also close to the set significance level. In subjects with Rh- factor, a statistically significant difference was found for only one trait (absence of mallets on the phalanges).
CONCLUSION: Although the number of subjects was relatively small, we can conclude that in the experimental group a higher frequency of recessive phenotypes for the examined traits was recorded, which indicates the genetic load of the subjects from this group. Correlation with Rh factor was observed in the case of subjects of the experimental group with Rh+ factor.
© 2021 Azra Metovic, Jasmin Musanovic, Nerman Ramic, Orhan Lepara, Damir Secic, Esad Pepic, Svjetlana Loga Zec, Senad Sljuka.

Entities:  

Keywords:  Rh factors; breast cancer; homozygous recessive; recessive trait

Mesh:

Substances:

Year:  2021        PMID: 35169367      PMCID: PMC8802679          DOI: 10.5455/medarh.2021.75.413-417

Source DB:  PubMed          Journal:  Med Arch        ISSN: 0350-199X


BACKGROUND

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide with more than 2 million new cases in 2020 (1). Its incidence and death rate have increased in the last three decades due to changing risk profile profiles, better cancer registration and detection. The number of BC risk factors is significant and includes both modified and non-modified factors. Currently, about 80% of patients with BC are individuals aged over 50 years. (2). Breast cancer is the most common malignant tumor in women in the world as a whole, which occurs when normal breast glandular cells change their properties and begin to grow uncontrollably, multiply and destroy the surrounding healthy tissue (3). Breast cancer in women is the second most common type of cancer and accounts for about 18% of all malignant tumors in women worldwide (4). In developed countries (including BiH) it is even at the first place. There are numerous classifications of malignant breast tumors (5, 6). The genes responsible for hereditary breast cancer (discovered in 1994 and 1995) are called Breast Cancer 1 and Breast Cancer 2, respectively, BRCA-1 and BRCA-2 (7). Women who inherit these mutations are at high risk of getting sick from this disease, according to some experts up to 80%. BRCA-1 mutations also increase the risk of ovarian cancer (8). These are large genes and their mutations are very numerous and affect different sites in the DNA chain (9, 10). Breast cancer is an important public health problem. Epidemiological studies have identified several risk factors for breast cancer, such as age, heredity, diet and lifestyle, reproductive activity, socioeconomic status and racial affiliation (11). Experimental molecular genetic studies have shown the role of mutagenic factors, sex hormones, free radicals and oncogenes. In order to examine the role of genetic factors in the development of breast cancer, numerous population-genetic and cytogenetic studies, studies of twins, and the association studies of this disease with certain blood-group systems and antigens have been conducted (12). Although there have been tremendous advances in elucidating genetic risk factors underlying both familial and sporadic breast cancer, much of the genetic contribution to breast cancer etiology remains unknown (13). The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance (14). Starting from the assumption that the manifestation of breast cancer can be based on the genetic dispositions of certain individuals, it seemed interesting to compare the population-genetic structure of cancer patients with the population-genetic structure of healthy individuals (15-18). Assumptions that the manifestation of breast cancer may be based on genetic predispositions, made it interesting to compare the population-genetic structure of breast cancer patients with the population-genetic structure of healthy individuals. A very suitable manner to establish possible differences between these two groups could be to examine the most striking morphological and physiological characteristics of humans, which could serve as parameters of population-genetic structure. The assumption that at the level of the examined phenotypes differences could be expected between patients with breast cancer and healthy (control) samples and can be explained in two ways: Genes on which the manifestation of breast cancer or resistance to the factors that cause this disease can simultaneously have a pleiotropic effect on a number of other characteristics and thus manifest themselves correlatively through them; Genetic loads resulting from increased recessive homozygosity for a number of characteristics, in persons with breast cancer are the cause of reduced resistance to external factors that cause this disease.

OBJECTIVE

* Examine the possible genetic basis of the Rh factor relationship with selected homozygous-recessive traits of females with breast cancer, and pre-diagnose the probability (assess the risk) of developing the disease in healthy women by analyzing homozygous-recessive traits (HRT). * Determine the existence of a potential statistically significant relationship between one or more HRTs with a certain type of Rh factor in patients. * Statistically process the data, determine the frequency of occurrence of certain HRTs and their relationship with Rh factor in subjects with breast cancer in relation to the control group. * Determining the existence of a potential statistically significant relationship between one or more HRTs with a particular type of Rh factor in obese individuals.

MATERIAL AND METHODS

This anthroposcopic-qualitative study includes two groups of subjects. Experimental group: Its included 40 female subjects with breast cancer. The criteria for inclusion in the experimental group was confirmation of the diagnosis based on official medical documentation, PH finding. The experimental group did not include persons who had other diagnoses related to malignant processes. Control group: Its included 40 healthy female subjects. The control group was obtained by random sampling, taking into account that there is no familial predisposition for the development of breast cancer. All respondents signed an informed consent form for participation in the study, which applied methodology that ensures their anonymity. A morphophysiological approach was performed to collect data. A variant of the phenotype of the studied traits was determined for each subject by direct observation and interviewing. Statistical analysis Statistical evaluation of the study results yielded more complete and comprehensive results that showed whether there was a significant statistical correlation between recessive alleles of selected HRT and Rh factor type in patients with breast cancer.

RESULTS

The “HRT test” was used in this study, which includes qualitative morphological and functional characteristics that are under the control of genetic factors and cover all regions of the human body: hair characteristics, facial features, pronunciation, tongue mobility, finger characteristics, hand characteristics and finger mobility (19-22). Table 1 present the frequency of HRT in the experimental and control groups in relation to Rh factor. The results are presented in absolute number, percentage and the p value.
Table 1.

Frequency of HRT in the examined groups in relation to Rh factor

TRAITEXPERIMENTAL GROUPCONTROL GROUP
N(40)Rh+(34)%Rh-(6)%pN(40)Rh+(33)%Rh-(7)%P
Flat scalp252161.76466.660.600171648.48114.280.105
Two flowers in the hair7720.58000.289000000
Soft hair343191.17350.000.033252060.60571.420.467
Real hair272470.58350.000.293221751.51571.420.297
Tied earlobe161441.17233.330.544241854.54685.710.134
An ear without Darwin’s nodule241955.88583.330.212211854.54342.850.441
Thin lips272264.70583.330.351262369.69342.850.179
Retracted teeth7617.64116.660.721339.09000.552
Retracted chin4411.76000.507326.06114.280.448
Absence of mallets242161.763500.456242060.60457.140.592
Narrow nostrils232058.823500.551221957.57342.850.383
Inability to bend the tongue longitudinally161235.29466.670.160131030.30342.850.408
Inability to bend the tongue backwards111132.35000.128439.09114.280.552
Speech defect “R”8720.59116.670.656113.03000.825
Right thumb over left2017503500.669231854.54571.420.351
Mobility of the distal part of the thumb8720.58116.660.6566618.18000.289
Ability to reach the forearm with the thumb325.88116.660.3949721.21228.570.504
Way of crossing arms, R-phenotype191750233.330.381221957.57342.850.383
Absence of mallets on the phalanges262367.643500.346342781.8171000.289
Three tendons at the root of the fist322779.41583.330.656282266.66685.710.306
Table 2 shows the frequency of HRT in the experimental and control groups in relation to the Rh+ factor of the subjects. The values are expressed in absolute numbers, percentage representation, and the p value.
Table 2.

Incidence of HRT in Rh+ subjects of the control and experimental groups

TRAITEXPERIMENTAL GROUP (34)CONTROL GRUPA (33)P
PresentAbsent%PresentAbsent%
Flat scalp211361.67161748.480.274
Two flowers in the hair72720.5903300.006
Soft hair31391.18201360.610.003
Real hair241070.59171651.520.109
Tied earlobe151944.12181554.550.393
An ear without Darwin’s nodule191555.88181554.550.912
Thin lips221264.71231069.700.664
Retracted teeth62817.653309.090.253
Retracted chin43011.762316.060.351
Absence of mallets211361.76201360.610.922
Narrow nostrils201458.82191457.580.918
Inability to bend the tongue longitudinally122235.29102330.300.664
Inability to bend the tongue backwards112332.353309.0910.019
Speech defect “R”72720.591323.030.027
Right thumb over left171750.00181554.550.710
Mobility of the distal part of the thumb72720.5962718.180.803
Ability to reach the forearm with the thumb2325.8872621.210.068
Way of crossing arms, R-phenotype171750.00191457.580.534
Absence of mallets on the phalanges231167.6527681.820.183
Three tendons at the root of the fist27779.41221166.670.239
Table 3 shows the frequency of HRT in the experimental and control groups in relation to the Rh factor of the subjects. The values are expressed in absolute numbers, percentage representation, and the p value.
Table 3.

Incidence of HRT in Rh-subjects of the experimental and control groups

TRAITEXPERIMENTAL GROUPCONTROL GROUPp
PresentAbsent%PresentAbsent%
Flat scalp4266.671614.290.083
Two flowers in the hair0600700
Soft hair3350.005271.430.413
Real hair3350.005271.430.413
Tied earlobe2433.336185.710.86
An ear without Darwin’s nodule5183.333442.860.179
Thin lips5183.333442.860.179
Retracted teeth1516.670700.462
Retracted chin0601614.290.538
Absence of mallets3350.004357.140.617
Narrow nostrils3350.003442.860.617
Inability to bend the tongue longitudinally4266.673442.860.383
Inability to bend the tongue backwards0601614.290.538
Speech defect “R”1516.670700.261
Right thumb over left3350.005271.430.413
Mobility of the distal part of the thumb1516.670700.462
Ability to reach the forearm with the thumb1516.672528.570.563
Way of crossing arms, R-phenotype2433.333442.860.587
Absence of mallets on the phalanges3350.000700.033
Three tendons at the root of the fist5183.336185.710.731

DISCUSSION

The etiology of breast cancer has not yet been fully elucidated. The efforts of scientists to reveal the mechanism of malignancy and risk factors, and certain markers are very widespread. Molecular techniques are the focus of this research. However, genetic predisposition or risk of diseases are also “marked” through the phenotypic manifestation of genes (21, 22). Population genetic studies of traits through the HRO test during our study are not processed in this way in the world, so the data obtained in our study can be considered a new understanding of the etiology of breast cancer. Thus, great attention is paid to HRT, not only in breast cancer, but also in others diseases (23). Possibility of correlation of several genes (which affects the phenotypic expression of one trait). These genes may be involved in regulatory processes of resistance to the studied disorder (24). The obtained results show an increased genetic load through an increase in recessive homozygosity, which in patients may be the cause of reduced resistance to external factors (25). These types of research present similar results for some other diseases, such as tumors of the urinary tract, tumors of other locations, endemic nephropathy, spinal dysraphism (26). The age difference in the examined groups does not affect the obtained results since the analyzed traits do not change over a lifetime. The correlation between HRT and Rh factors showed that a larger number of patients with Rh+ factor, who had significant statistical differences in the examined HRTs (found a difference in 4 examined HRTs). The difference in the population-genetic structure of the experimental and control group with Rh-factor is in only one feature. Therefore, we can state that there is no significant Rh factor in the examined sample associations with HRT in breast cancer patients. The most likely mechanism in the progress of an association among “ABO” and “Rhesus” blood types and the incidence of breast cancer has not been established yet. The current genome-wide association studies suggest that the “ABO” blood type antigen increases the incidence of breast cancer. The genetic factors are most likely involved in the etiology of breast cancer (27-30).

CONCLUSIONS

Based on all the above, the following can be concluded: * The result in the group of Rh+ subjects indicate the correlation of this type of Rh factor with the development of breast cancer, given the frequency of the phenotype of homozygous-recessive traits in them. * A statistically significant difference was found for 4 traits, and three are still close to the significance limit. Females with Rh+ factor are at higher risk of developing breast cancer. * In subjects with Rh- factor, a statistically significant difference was found for only one trait (absence of hair on the phalanges), so that the correlation of this Rh factor with breast cancer has not been established. * Although the number of respondents was relatively small, the conclusion is that it is in the experimental group a higher frequency of recessive phenotypes of the examined traits was noted, indicating genetic load of respondents from this group. Correlation with Rh factor was observed in the case of the subjects experimental groups with Rh+ factor. * It is necessary to expand the research, both in terms of the number of respondents and the introduction of new methodologies. * The application of the HRO test in the future may be useful in detecting genotypes susceptible to various diseases.
  18 in total

Review 1.  Rare-variant association analysis: study designs and statistical tests.

Authors:  Seunggeung Lee; Gonçalo R Abecasis; Michael Boehnke; Xihong Lin
Journal:  Am J Hum Genet       Date:  2014-07-03       Impact factor: 11.025

2.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

3.  Susceptibility to lung tuberculosis--a population-genetic study.

Authors:  Dragica Pesut
Journal:  Med Pregl       Date:  2004

4.  A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Authors:  Afshan Siddiq; Fergus J Couch; Gary K Chen; Sara Lindström; Diana Eccles; Robert C Millikan; Kyriaki Michailidou; Daniel O Stram; Lars Beckmann; Suhn Kyong Rhie; Christine B Ambrosone; Kristiina Aittomäki; Pilar Amiano; Carmel Apicella; Laura Baglietto; Elisa V Bandera; Matthias W Beckmann; Christine D Berg; Leslie Bernstein; Carl Blomqvist; Hiltrud Brauch; Louise Brinton; Quang M Bui; Julie E Buring; Saundra S Buys; Daniele Campa; Jane E Carpenter; Daniel I Chasman; Jenny Chang-Claude; Constance Chen; Françoise Clavel-Chapelon; Angela Cox; Simon S Cross; Kamila Czene; Sandra L Deming; Robert B Diasio; W Ryan Diver; Alison M Dunning; Lorraine Durcan; Arif B Ekici; Peter A Fasching; Heather Spencer Feigelson; Laura Fejerman; Jonine D Figueroa; Olivia Fletcher; Dieter Flesch-Janys; Mia M Gaudet; Susan M Gerty; Jorge L Rodriguez-Gil; Graham G Giles; Carla H van Gils; Andrew K Godwin; Nikki Graham; Dario Greco; Per Hall; Susan E Hankinson; Arndt Hartmann; Rebecca Hein; Judith Heinz; Robert N Hoover; John L Hopper; Jennifer J Hu; Scott Huntsman; Sue A Ingles; Astrid Irwanto; Claudine Isaacs; Kevin B Jacobs; Esther M John; Christina Justenhoven; Rudolf Kaaks; Laurence N Kolonel; Gerhard A Coetzee; Mark Lathrop; Loic Le Marchand; Adam M Lee; I-Min Lee; Timothy Lesnick; Peter Lichtner; Jianjun Liu; Eiliv Lund; Enes Makalic; Nicholas G Martin; Catriona A McLean; Hanne Meijers-Heijboer; Alfons Meindl; Penelope Miron; Kristine R Monroe; Grant W Montgomery; Bertram Müller-Myhsok; Stefan Nickels; Sarah J Nyante; Curtis Olswold; Kim Overvad; Domenico Palli; Daniel J Park; Julie R Palmer; Harsh Pathak; Julian Peto; Paul Pharoah; Nazneen Rahman; Fernando Rivadeneira; Daniel F Schmidt; Rita K Schmutzler; Susan Slager; Melissa C Southey; Kristen N Stevens; Hans-Peter Sinn; Michael F Press; Eric Ross; Elio Riboli; Paul M Ridker; Fredrick R Schumacher; Gianluca Severi; Isabel Dos Santos Silva; Jennifer Stone; Malin Sund; William J Tapper; Michael J Thun; Ruth C Travis; Clare Turnbull; Andre G Uitterlinden; Quinten Waisfisz; Xianshu Wang; Zhaoming Wang; Joellen Weaver; Rüdiger Schulz-Wendtland; Lynne R Wilkens; David Van Den Berg; Wei Zheng; Regina G Ziegler; Elad Ziv; Heli Nevanlinna; Douglas F Easton; David J Hunter; Brian E Henderson; Stephen J Chanock; Montserrat Garcia-Closas; Peter Kraft; Christopher A Haiman; Celine M Vachon
Journal:  Hum Mol Genet       Date:  2012-09-13       Impact factor: 6.150

Review 5.  Effects of age on the detection and management of breast cancer.

Authors:  Andrew McGuire; James A L Brown; Carmel Malone; Ray McLaughlin; Michael J Kerin
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

Review 6.  The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance.

Authors:  Andrew D Skol; Mark M Sasaki; Kenan Onel
Journal:  Breast Cancer Res       Date:  2016-10-03       Impact factor: 6.466

7.  Association of ABO and Rh blood groups with breast cancer.

Authors:  Sultan Ayoub Meo; Faryal Suraya; Badar Jamil; Fwziah Al Rouq; Anusha Sultan Meo; Kamran Sattar; Mohammad Javed Ansari; Saleh A Alasiri
Journal:  Saudi J Biol Sci       Date:  2017-02-03       Impact factor: 4.219

8.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

9.  Genome-wide association studies identify four ER negative-specific breast cancer risk loci.

Authors:  Montserrat Garcia-Closas; Fergus J Couch; Sara Lindstrom; Kyriaki Michailidou; Marjanka K Schmidt; Mark N Brook; Nick Orr; Suhn Kyong Rhie; Elio Riboli; Heather S Feigelson; Loic Le Marchand; Julie E Buring; Diana Eccles; Penelope Miron; Peter A Fasching; Hiltrud Brauch; Jenny Chang-Claude; Jane Carpenter; Andrew K Godwin; Heli Nevanlinna; Graham G Giles; Angela Cox; John L Hopper; Manjeet K Bolla; Qin Wang; Joe Dennis; Ed Dicks; Will J Howat; Nils Schoof; Stig E Bojesen; Diether Lambrechts; Annegien Broeks; Irene L Andrulis; Pascal Guénel; Barbara Burwinkel; Elinor J Sawyer; Antoinette Hollestelle; Olivia Fletcher; Robert Winqvist; Hermann Brenner; Arto Mannermaa; Ute Hamann; Alfons Meindl; Annika Lindblom; Wei Zheng; Peter Devillee; Mark S Goldberg; Jan Lubinski; Vessela Kristensen; Anthony Swerdlow; Hoda Anton-Culver; Thilo Dörk; Kenneth Muir; Keitaro Matsuo; Anna H Wu; Paolo Radice; Soo Hwang Teo; Xiao-Ou Shu; William Blot; Daehee Kang; Mikael Hartman; Suleeporn Sangrajrang; Chen-Yang Shen; Melissa C Southey; Daniel J Park; Fleur Hammet; Jennifer Stone; Laura J Van't Veer; Emiel J Rutgers; Artitaya Lophatananon; Sarah Stewart-Brown; Pornthep Siriwanarangsan; Julian Peto; Michael G Schrauder; Arif B Ekici; Matthias W Beckmann; Isabel Dos Santos Silva; Nichola Johnson; Helen Warren; Ian Tomlinson; Michael J Kerin; Nicola Miller; Federick Marme; Andreas Schneeweiss; Christof Sohn; Therese Truong; Pierre Laurent-Puig; Pierre Kerbrat; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Roger L Milne; Jose Ignacio Arias Perez; Primitiva Menéndez; Heiko Müller; Volker Arndt; Christa Stegmaier; Peter Lichtner; Magdalena Lochmann; Christina Justenhoven; Yon-Dschun Ko; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Dario Greco; Tuomas Heikkinen; Hidemi Ito; Hiroji Iwata; Yasushi Yatabe; Natalia N Antonenkova; Sara Margolin; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Rosemary Balleine; Chiu-Chen Tseng; David Van Den Berg; Daniel O Stram; Patrick Neven; Anne-Sophie Dieudonné; Karin Leunen; Anja Rudolph; Stefan Nickels; Dieter Flesch-Janys; Paolo Peterlongo; Bernard Peissel; Loris Bernard; Janet E Olson; Xianshu Wang; Kristen Stevens; Gianluca Severi; Laura Baglietto; Catriona McLean; Gerhard A Coetzee; Ye Feng; Brian E Henderson; Fredrick Schumacher; Natalia V Bogdanova; France Labrèche; Martine Dumont; Cheng Har Yip; Nur Aishah Mohd Taib; Ching-Yu Cheng; Martha Shrubsole; Jirong Long; Katri Pylkäs; Arja Jukkola-Vuorinen; Saila Kauppila; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Robertus A E M Tollenaar; Caroline M Seynaeve; Mieke Kriege; Maartje J Hooning; Ans M W van den Ouweland; Carolien H M van Deurzen; Wei Lu; Yu-Tang Gao; Hui Cai; Sabapathy P Balasubramanian; Simon S Cross; Malcolm W R Reed; Lisa Signorello; Qiuyin Cai; Mitul Shah; Hui Miao; Ching Wan Chan; Kee Seng Chia; Anna Jakubowska; Katarzyna Jaworska; Katarzyna Durda; Chia-Ni Hsiung; Pei-Ei Wu; Jyh-Cherng Yu; Alan Ashworth; Michael Jones; Daniel C Tessier; Anna González-Neira; Guillermo Pita; M Rosario Alonso; Daniel Vincent; Francois Bacot; Christine B Ambrosone; Elisa V Bandera; Esther M John; Gary K Chen; Jennifer J Hu; Jorge L Rodriguez-Gil; Leslie Bernstein; Michael F Press; Regina G Ziegler; Robert M Millikan; Sandra L Deming-Halverson; Sarah Nyante; Sue A Ingles; Quinten Waisfisz; Helen Tsimiklis; Enes Makalic; Daniel Schmidt; Minh Bui; Lorna Gibson; Bertram Müller-Myhsok; Rita K Schmutzler; Rebecca Hein; Norbert Dahmen; Lars Beckmann; Kirsimari Aaltonen; Kamila Czene; Astrid Irwanto; Jianjun Liu; Clare Turnbull; Nazneen Rahman; Hanne Meijers-Heijboer; Andre G Uitterlinden; Fernando Rivadeneira; Curtis Olswold; Susan Slager; Robert Pilarski; Foluso Ademuyiwa; Irene Konstantopoulou; Nicholas G Martin; Grant W Montgomery; Dennis J Slamon; Claudia Rauh; Michael P Lux; Sebastian M Jud; Thomas Bruning; Joellen Weaver; Priyanka Sharma; Harsh Pathak; Will Tapper; Sue Gerty; Lorraine Durcan; Dimitrios Trichopoulos; Rosario Tumino; Petra H Peeters; Rudolf Kaaks; Daniele Campa; Federico Canzian; Elisabete Weiderpass; Mattias Johansson; Kay-Tee Khaw; Ruth Travis; Françoise Clavel-Chapelon; Laurence N Kolonel; Constance Chen; Andy Beck; Susan E Hankinson; Christine D Berg; Robert N Hoover; Jolanta Lissowska; Jonine D Figueroa; Daniel I Chasman; Mia M Gaudet; W Ryan Diver; Walter C Willett; David J Hunter; Jacques Simard; Javier Benitez; Alison M Dunning; Mark E Sherman; Georgia Chenevix-Trench; Stephen J Chanock; Per Hall; Paul D P Pharoah; Celine Vachon; Douglas F Easton; Christopher A Haiman; Peter Kraft
Journal:  Nat Genet       Date:  2013-04       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.